



KILLING CANCER CELLS THROUGH CERENKOV-INDUCED PHOTODYNAMIC EFFECT

JOEL DAOUK
CRAN UMR7039 – PROJET SYRANNO



UNIVERSITÉ
DE LORRAINE


BioSiS

CLINICAL CONTEXT

Glioblastoma (GBM)

- Grade IV astrocytoma
→ Infiltrative and invasive cancer cells
→ Most fast-growing and aggressive brain tumor

- 2400 cases/year in France
- Median age: 64 years



Current standard treatment

- **Stupp protocole**
 - ✓ Tumor resection
 - ✓ + Chemotherapy (Temozolomide)
 - ✓ + External radiotherapy (X ray → 60 Gy)

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma →


Roger Stupp, M.D., Warren P. Mason, M.D., Martin J. van den Bent, M.D., Michael Weller, M.D., Barbara Fisher, M.D., Martin J.B. Taphoorn, M.D., Karl Belanger, M.D., Alba A. Brandes, M.D., Christine Marosi, M.D., Ulrich Bogdahn, M.D., Jürgen Curschmann, M.D., Robert C. Janzer, M.D., Samuel K. Ludwin, M.D., Thierry Gorlia, M.Sc., Anouk Allgeier, Ph.D., Denis Lacombe, M.D., J. Gregory Cairncross, M.D., Elizabeth Eisenhauer, M.D., and René O. Mirimanoff, M.D., for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group*

< 5 year-GBM survival rate is only for 6.8% patients
→ **Alternative ?**


→ **Photodynamic therapy (PDT)**

*Low light penetration depth is the main limiting point
Poor tissue penetration*

PHOTODYNAMIC THERAPY





PHOTODYNAMIC THERAPY JABLONSKI DIAGRAM



PHOTODYNAMIC THERAPY PRINCIPLE

- **Photosensitizer properties**
 - Non cytotoxic without light
 - High singlet oxygen quantum yield
 - Large spectral overlap with light source



PHOTODYNAMIC THERAPY: CLINICALLY FEASIBLE

INDYGO

Etude de Phase 1 de thérapie photodynamique peropératoire du glioblastome




Sponsor de l'étude : CHU de Lille

Objectif principal : Evaluer la faisabilité de la réalisation de la PDT per opératoire au cours de la chirurgie d'exérèse du glioblastome, sans toxicité immédiate inacceptable.


**PHOTOSENSITIZER
GRAFTED WITHIN
THE NANOPARTICLES**

**HOMING PEPTIDE
TARGETING
NRP-1**


**IMAGING
AGENT
FOR MRI**




**SILICA-BASED
NANOPARTICLES**



PHOTOSENSITIZER




DOTA (Gadolinium chélaté)
About 10 DOTAs/nanoparticle




DOTA	
Identification	
Synonyms	acide 1,4,7,10-tétrazacyclododécane-1,4,7,10-tétraacétique

Theranostic Nanoparticles
(MRI-SPECT/PET-fluorescence-Therapy)



AGuIX® Nanodrug




**Preclinical
Multimodal
Nanoparticles**




CheMatech
macrocycle design technologies

nano+^h
Value-Added Nanotechnology




BioSiS

PHOTODYNAMIC THERAPY PRINCIPLE



652 NM, 26 J, 8MIN
ONLY 1 SESSION

PHOTODYNAMIC THERAPY PRINCIPLE



International Journal of Nanomedicine

Dovepress

open access to scientific and medical research

Open Access Full Text Article

ORIGINAL RESEARCH

Multiscale Selectivity and in vivo Biodistribution of NRP-1-Targeted Theranostic AGuIX Nanoparticles for PDT of Glioblastoma

Mickaël Gries¹
Noémie Thomas¹
Joël Daouk¹
Paul Bascchi²



Background: Local recurrences of glioblastoma (GBM) after heavy standard treatments remain frequent and lead to a poor prognostic. Major challenges are the infiltrative part of the tumor tissue which is the ultimate cause of recurrence. The therapeutic arsenal faces the difficulty of eradicating this infiltrating part of the tumor tissue while increasing the targeting

This article was published in the following Dove Press journal:
International Journal of Nanomedicine

CERENKOV-INDUCED PHOTODYNAMIC THERAPY

NANOPARTICLE INTEREST:

- FUNCTIONALIZED AGUIX-DERIVED
- NANOSCINTILLATOR CHELATES



Schneller et al, Pharmaceuticals, 2023

CERENKOV-INDUCED PHOTODYNAMIC THERAPY







Figure 2. Cerenkov spectrum for ^{18}F , ^{68}Ga and ^{89}Zr decay in biological medium. Spectra were defined between 100 and 650 nm. To ease reading, number of photons are expressed relatively to ^{18}F at 100 nm.




Daouk et al, Radiation, 2020

SINGLET OXYGEN PRODUCTION



Kinetics of singlet oxygen production by AGuIX@Tb-P1 under Gallium-68 exposure. 7.35 μM AGuIX@Tb-P1 (P1 equivalent), 10 μM fluorescent probe and 15–20 MBq⁽⁶⁸⁾.

EFFECT ON CELL SURVIVAL




Impact of Gallium-68 deposition into U-251 MG cells.

- SCINTILLATOR IMPROVES TREATMENT EFFICACY
- 3 MBQ OF ⁶⁸Ga REACH THE SAME EFFECT THAN A 2 GY X-RAY-PDT IRRADIATION
- 3 MBQ OF ⁶⁸Ga REACH THE SAME EFFECT THAN A 4 GY X-RAY IRRADIATION WITHOUT PDT


Schneller et al, Pharmaceuticals, 2023

EFFECT ON NUCLEAR DNA




- 2 Gy X-ray + NP Tb-P1 → increased H2AX fluorescence = cumulative effect on DNA
- 2 Gy X-ray + NP Tb → H2AX fluorescence not increased = no radiosensitizing effect from Tb
- 3 MBq ⁶⁸Ga (~10⁻⁴ Gy) → Basal H2AX signal = no DNA alteration

EFFECT ON OXIDATIVE STRESS RESPONSE




➤ Nuclear Ubiquitinated Nrf2 increased after X-ray or ⁶⁸Ga irradiation → transcriptional activity increased



➤ HO-1 increased with irradiation → increased anti-oxidative activity

➤ 3 MBq ⁶⁸Ga yields same HO-1 expression than X-ray 4 Gy

EFFECT ON OXIDATIVE STRESS RESPONSE



CONCLUSION

- **High energy charged particles produce enough Cerenkov photons to induce a PDT effect**
- **Cerenkov-induced PDT can kill cancer cells with a much lower deposited dose compared to radiation therapy**
- **Cell death is not linked to nuclear DNA damage**
- **Oxidative stress seems to be the main involved pathway**